Komori
Kaneka (4118) · PolicyAdvanced

Cross-shareholdings to maintain and strengthen business relationships

First written in FY2017. 6 of 7 entries say "Advanced", first in FY2019. Latest entry: FY2026.

7entries
10years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017AdvancedFY2019 – FY20262017: 120172018: 020182019: 120192020: 020202021: 120212022: 020222023: 120232024: 020242025: 020252026: 32026
Same theme, other companies
Business relationships and sales policy through strategic shareholdingsA theme 607 companies write about · 0 as a headwind · 550 as a tailwind

The whole theme swung hardest in 2019: 17 of 136 companies on the "Worse" side.

68 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 612 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「We hold the minimum necessary cross-shareholdings for the purposes of maintaining and strengthening business relationships and pursuing business and capital alliances. For cross-shareholdings, we conduct a comprehensive review of the appropriateness of the holding purpose and the economic rationality of the returns and risks associated with the holdings, review each year whether to continue holding them, and reduce holdings judged to have limited necessity.」

    The cross-shareholdings comprised 45 unlisted and 41 listed issues, and 13 listed issues were sold during the current fiscal year for ¥26,710 million. The policy of holding only the minimum necessary investments and reducing holdings is being implemented.
  2. FY2023AdvancedAnnual report

    「We hold the minimum necessary cross-shareholdings for the purposes of maintaining and strengthening business relationships and pursuing business and capital alliances. For cross-shareholdings, we conduct a comprehensive review of the appropriateness of the holding purpose and the economic rationality of the returns and risks associated with the holdings, review each year whether to continue holding them, and reduce holdings judged to have limited necessity.」

    The policy for cross-shareholdings has been maintained. During the current fiscal year, we held 51 unlisted and 68 listed issues, while selling 4 issues for ¥2,283 million.
  3. FY2021AdvancedAnnual report

    「For cross-shareholdings, we conduct a comprehensive review of the appropriateness of the holding purpose and the economic rationality of the returns and risks associated with the holdings, review each year whether to continue holding them, and reduce holdings judged to have limited necessity.」

    The cross-shareholdings comprise 52 unlisted and 72 listed securities, for a total of 124 issues. During the current fiscal year, 4 issues were sold for ¥859 million as part of the reduction of holdings.
  4. FY2019AdvancedAnnual report

    「For cross-shareholdings, we conduct a comprehensive review of the appropriateness of the holding purpose and the economic rationality of the returns and risks associated with the holdings, review each year whether to continue holding them, and reduce holdings judged to have limited necessity.」

    The policy for cross-shareholdings specifies annual reviews of whether holdings should be retained and reductions in securities deemed to have limited necessity.
  5. FY2017First statedAnnual report

    「We hold these investments for the purpose of building, maintaining and strengthening business relationships over the medium to long term.」

    We hold 136 investment securities for purposes other than pure investment, with a total balance-sheet value of ¥54,087 million. Their primary purpose is to build, maintain and strengthen business relationships.
Moved together

"Global expansion of medical, pharmaceutical, and functional food ingredients" moved the same way as this thread, in the same document, in 6 of its 7 moves.

665554★123456
  1. ★This thread
  2. 1Global expansion of medical, pharmaceutical, and functional food ingredients6×
  3. 2Addressing the Microplastics Problem with Polymers That Biodegrade in Seawater6×
  4. 3Transformation of the Business Portfolio and Shift Toward Growth Areas5×
  5. 4Stable shareholder returns targeting a 30% consolidated payout ratio5×
  6. 5Growth in Global Markets Centered on Overseas Regional Headquarters Companies5×
  7. 6Improving the conversion efficiency of heterojunction solar cells4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kaneka yet. It last moved in the Management plan of 2026-05-29: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.